Arterra Bioscience S.p.A. (BIT:ARBS)
Italy · Delayed Price · Currency is EUR 3.020
-0.080 (-2.58%)
Oct 16, 2026, 5:35 PM CET
Arterra Bioscience Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 5.11 | 4.65 | 4.17 | 3.3 | 3.56 | 3.83 |
Other Revenue | 0.09 | 0.06 | 0 | 0.03 | 0.03 | 0.92 |
| 5.2 | 4.7 | 4.17 | 3.34 | 3.59 | 4.74 | |
Revenue Growth | 7.89% | 12.74% | 25.08% | -7.10% | -24.27% | 13.64% |
Cost of Revenue | 2.01 | 1.77 | 1.76 | 1.49 | 1.15 | 1.44 |
Gross Profit | 3.19 | 2.94 | 2.41 | 1.85 | 2.44 | 3.3 |
Selling, General & Admin | 2.16 | 1.94 | 1.69 | 1.56 | 1.47 | 1.39 |
Amortization of Goodwill & Intangibles | 0.01 | 0.01 | 0.03 | 0.18 | 0.18 | 0.19 |
Other Operating Expenses | -1.19 | -1.22 | -0.99 | -1.3 | -1.16 | 0.18 |
Operating Expenses | 1.28 | 1.01 | 1.04 | 0.79 | 0.84 | 2.06 |
Operating Income | 1.91 | 1.93 | 1.37 | 1.06 | 1.6 | 1.25 |
Interest Expense | -0 | -0 | -0 | -0.01 | -0.01 | -0.01 |
Interest & Investment Income | 0.06 | 0.2 | 0.2 | 0.16 | 0.2 | - |
Earnings From Equity Investments | - | - | - | - | - | 0 |
Other Non Operating Income (Expenses) | 0.14 | - | 0.13 | 0.09 | 0 | 0.03 |
EBT Excluding Unusual Items | 2.11 | 2.13 | 1.7 | 1.3 | 1.8 | 1.27 |
Asset Writedown | -0.13 | -0.13 | - | - | - | - |
Pretax Income | 1.97 | 2 | 1.7 | 1.3 | 1.8 | 1.27 |
Income Tax Expense | 0.31 | -0.01 | 0.36 | 0.23 | 0.38 | 0.16 |
Net Income | 1.66 | 2.01 | 1.34 | 1.08 | 1.41 | 1.11 |
Net Income to Common | 1.66 | 2.01 | 1.34 | 1.08 | 1.41 | 1.11 |
Net Income Growth | -12.68% | 50.09% | 24.21% | -23.89% | 27.33% | 0.18% |
Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | - | - |
Shares Outstanding (Diluted) | 7 | 7 | 7 | 7 | - | - |
Shares Change | - | - | - | - | - | - |
EPS (Basic) | 0.25 | 0.30 | 0.20 | 0.16 | - | - |
EPS (Diluted) | 0.25 | 0.30 | 0.20 | 0.16 | - | - |
EPS Growth | - | 50.09% | 24.21% | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1.2 | 1.54 | 0.42 | 0.96 | 1.3 | 0.86 |
Free Cash Flow Per Share | 0.18 | 0.23 | 0.06 | 0.14 | - | - |
Dividend Per Share | - | - | 0.130 | 0.100 | 0.100 | 0.050 |
Dividend Growth | - | - | 30.00% | 0% | 100.00% | - |
Gross Margin | 61.35% | 62.44% | 57.85% | 55.46% | 68.03% | 69.69% |
Operating Margin | 36.72% | 41.06% | 32.90% | 31.75% | 44.57% | 26.32% |
Profit Margin | 31.99% | 42.64% | 32.03% | 32.26% | 39.38% | 23.42% |
Free Cash Flow Margin | 23.13% | 32.71% | 10.15% | 28.77% | 36.23% | 18.05% |
EBITDA | 2.22 | 2.22 | 1.71 | 1.59 | 2.13 | 1.74 |
EBITDA Margin | 42.74% | 47.22% | 41.03% | 47.70% | 59.38% | 36.60% |
D&A For EBITDA | 0.31 | 0.29 | 0.34 | 0.53 | 0.53 | 0.49 |
EBIT | 1.91 | 1.93 | 1.37 | 1.06 | 1.6 | 1.25 |
EBIT Margin | 36.72% | 41.06% | 32.90% | 31.75% | 44.57% | 26.32% |
Effective Tax Rate | 15.75% | - | 21.44% | 17.36% | 21.33% | 12.83% |
Revenue as Reported | 6.45 | 6.12 | 5.27 | 4.95 | 5.3 | 4.61 |